Mepolizumab Long-term Access Program (EGPA)

Full Name: Mepolizumab Long-term Access Program for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-Care Therapy
Study Dates: 2016-2018
NCT #: NCT03298061
Study Findings: This study enabled subjects who participated in the MEA115921 study to continue treatment with mepolizumab.